MarketPulse
A

$AVR

2 articles found
2 positive
0 negative
0 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Anteris Lands Medicare Reimbursement for PARADIGM Heart Valve Trial

Anteris Technologies secures CMS reimbursement eligibility for its PARADIGM Trial evaluating DurAVR transcatheter heart valve in 1,000 patients, accelerating U.S. site activation.
AVRclinical trialPARADIGM Trial
GlobeNewswire Inc.GlobeNewswire Inc.··Anteris Technologies Global Corp.

Anteris Secures $320M Funding as DurAVR Heart Valve Advances to Global Trials

Anteris secures $320M funding to advance DurAVR heart valve through global trials, with FDA approval and increased clinical development spending.
MDTAVRFDA approvalclinical trial